Table of Contents Table of Contents 2 Introduction 7 Crohn’s Disease (Regional Enteritis) Overview 8 Therapeutics Development 9 Crohn’s Disease (Regional Enteritis) - Therapeutics under Development by Companies 11 Crohn’s Disease (Regional Enteritis) - Therapeutics under Investigation by Universities/Institutes 19 Crohn’s Disease (Regional Enteritis) - Pipeline Products Glance 20 Crohn’s Disease (Regional Enteritis) - Products under Development by Companies 24 Crohn’s Disease (Regional Enteritis) - Products under Investigation by Universities/Institutes 33 Crohn’s Disease (Regional Enteritis) - Companies Involved in Therapeutics Development 34 Crohn’s Disease (Regional Enteritis) - Therapeutics Assessment 116 Drug Profiles 133 Crohn’s Disease (Regional Enteritis) - Recent Pipeline Updates 327 Crohn’s Disease (Regional Enteritis) - Dormant Projects 436 Crohn’s Disease (Regional Enteritis) - Discontinued Products 447 Crohn’s Disease (Regional Enteritis) - Product Development Milestones 449 Appendix 456

List of Tables Number of Products under Development for Crohn’s Disease (Regional Enteritis), H1 2016 24 Number of Products under Development for Crohn’s Disease (Regional Enteritis) - Comparative Analysis, H1 2016 25 Number of Products under Development by Companies, H1 2016 27 Number of Products under Development by Companies, H1 2016 (Contd..1) 28 Number of Products under Development by Companies, H1 2016 (Contd..2) 29 Number of Products under Development by Companies, H1 2016 (Contd..3) 30 Number of Products under Development by Companies, H1 2016 (Contd..4) 31 Number of Products under Development by Companies, H1 2016 (Contd..5) 32 Number of Products under Development by Companies, H1 2016 (Contd..6) 33 Number of Products under Investigation by Universities/Institutes, H1 2016 34 Comparative Analysis by Late Stage Development, H1 2016 35 Comparative Analysis by Clinical Stage Development, H1 2016 36 Comparative Analysis by Early Stage Development, H1 2016 37 Comparative Analysis by Unknown Stage Development, H1 2016 38 Products under Development by Companies, H1 2016 39 Products under Development by Companies, H1 2016 (Contd..1) 40 Products under Development by Companies, H1 2016 (Contd..2) 41 Products under Development by Companies, H1 2016 (Contd..3) 42 Products under Development by Companies, H1 2016 (Contd..4) 43 Products under Development by Companies, H1 2016 (Contd..5) 44 Products under Development by Companies, H1 2016 (Contd..6) 45 Products under Development by Companies, H1 2016 (Contd..7) 46 Products under Development by Companies, H1 2016 (Contd..8) 47 Products under Investigation by Universities/Institutes, H1 2016 48 Crohn’s Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, H1 2016 49 Crohn’s Disease (Regional Enteritis) - Pipeline by 4SC AG, H1 2016 50 Crohn’s Disease (Regional Enteritis) - Pipeline by AB Science SA, H1 2016 51 Crohn’s Disease (Regional Enteritis) - Pipeline by AbbVie Inc., H1 2016 52 Crohn’s Disease (Regional Enteritis) - Pipeline by Alfa Wassermann S.p.A, H1 2016 53 Crohn’s Disease (Regional Enteritis) - Pipeline by Amgen Inc., H1 2016 54 Crohn’s Disease (Regional Enteritis) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 55 Crohn’s Disease (Regional Enteritis) - Pipeline by Arena Pharmaceuticals, Inc., H1 2016 56 Crohn’s Disease (Regional Enteritis) - Pipeline by Avaxia Biologics, Inc., H1 2016 57 Crohn’s Disease (Regional Enteritis) - Pipeline by BioAtla, LLC, H1 2016 58 Crohn’s Disease (Regional Enteritis) - Pipeline by BIOCAD, H1 2016 59 Crohn’s Disease (Regional Enteritis) - Pipeline by BioLingus AG, H1 2016 60 Crohn’s Disease (Regional Enteritis) - Pipeline by Bionovis SA, H1 2016 61 Crohn’s Disease (Regional Enteritis) - Pipeline by BioTherapeutics Inc., H1 2016 62 Crohn’s Disease (Regional Enteritis) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 63 Crohn’s Disease (Regional Enteritis) - Pipeline by Calypso Biotech SA, H1 2016 64 Crohn’s Disease (Regional Enteritis) - Pipeline by Celgene Corporation, H1 2016 65 Crohn’s Disease (Regional Enteritis) - Pipeline by Celltrion, Inc., H1 2016 66 Crohn’s Disease (Regional Enteritis) - Pipeline by ChemoCentryx, Inc., H1 2016 67 Crohn’s Disease (Regional Enteritis) - Pipeline by ChironWells GmbH, H1 2016 68 Crohn’s Disease (Regional Enteritis) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 69 Crohn’s Disease (Regional Enteritis) - Pipeline by CLL Pharma, H1 2016 70 Crohn’s Disease (Regional Enteritis) - Pipeline by Commence Bio, Inc., H1 2016 71 Crohn’s Disease (Regional Enteritis) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 72 Crohn’s Disease (Regional Enteritis) - Pipeline by DBV Technologies S.A., H1 2016 73 Crohn’s Disease (Regional Enteritis) - Pipeline by Effimune SAS, H1 2016 74 Crohn’s Disease (Regional Enteritis) - Pipeline by Eisai Co., Ltd., H1 2016 75 Crohn’s Disease (Regional Enteritis) - Pipeline by Eli Lilly and Company, H1 2016 76 Crohn’s Disease (Regional Enteritis) - Pipeline by Enterome Bioscience SA, H1 2016 77 Crohn’s Disease (Regional Enteritis) - Pipeline by Enzo Biochem, Inc., H1 2016 78 Crohn’s Disease (Regional Enteritis) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 79 Crohn’s Disease (Regional Enteritis) - Pipeline by Ferring International Center S.A., H1 2016 80 Crohn’s Disease (Regional Enteritis) - Pipeline by Galapagos NV, H1 2016 81 Crohn’s Disease (Regional Enteritis) - Pipeline by Genentech, Inc., H1 2016 82 Crohn’s Disease (Regional Enteritis) - Pipeline by Genfit SA, H1 2016 83 Crohn’s Disease (Regional Enteritis) - Pipeline by Genor BioPharma Co., Ltd., H1 2016 84 Crohn’s Disease (Regional Enteritis) - Pipeline by Gilead Sciences, Inc., H1 2016 85 Crohn’s Disease (Regional Enteritis) - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 86 Crohn’s Disease (Regional Enteritis) - Pipeline by Immune Response BioPharma, Inc., H1 2016 87 Crohn’s Disease (Regional Enteritis) - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2016 88 Crohn’s Disease (Regional Enteritis) - Pipeline by Innovate Biopharmaceuticals, Inc., H1 2016 89 Crohn’s Disease (Regional Enteritis) - Pipeline by Innovent Biologics, Inc., H1 2016 90 Crohn’s Disease (Regional Enteritis) - Pipeline by Johnson & Johnson, H1 2016 91 Crohn’s Disease (Regional Enteritis) - Pipeline by Jyant Technologies, Inc., H1 2016 92 Crohn’s Disease (Regional Enteritis) - Pipeline by Kineta, Inc., H1 2016 93 Crohn’s Disease (Regional Enteritis) - Pipeline by Kymab Limited, H1 2016 94 Crohn’s Disease (Regional Enteritis) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 95 Crohn’s Disease (Regional Enteritis) - Pipeline by Mabion SA, H1 2016 96 Crohn’s Disease (Regional Enteritis) - Pipeline by MedImmune, LLC, H1 2016 97 Crohn’s Disease (Regional Enteritis) - Pipeline by Mesoblast Limited, H1 2016 98 Crohn’s Disease (Regional Enteritis) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 99 Crohn’s Disease (Regional Enteritis) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 100 Crohn’s Disease (Regional Enteritis) - Pipeline by Mycenax Biotech Inc., H1 2016 101 Crohn’s Disease (Regional Enteritis) - Pipeline by Neovacs SA, H1 2016 102 Crohn’s Disease (Regional Enteritis) - Pipeline by Ocata Therapeutics, Inc., H1 2016 103 Crohn’s Disease (Regional Enteritis) - Pipeline by Oncobiologics, Inc., H1 2016 104 Crohn’s Disease (Regional Enteritis) - Pipeline by Oncodesign SA, H1 2016 105 Crohn’s Disease (Regional Enteritis) - Pipeline by Pfenex Inc., H1 2016 106 Crohn’s Disease (Regional Enteritis) - Pipeline by Pfizer Inc., H1 2016 107 Crohn’s Disease (Regional Enteritis) - Pipeline by Pluristem Therapeutics Inc., H1 2016 108 Crohn’s Disease (Regional Enteritis) - Pipeline by Protagonist Therapeutics Inc., H1 2016 109 Crohn’s Disease (Regional Enteritis) - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 110 Crohn’s Disease (Regional Enteritis) - Pipeline by Qu Biologics Inc., H1 2016 111 Crohn’s Disease (Regional Enteritis) - Pipeline by Re-Pharm Limited, H1 2016 112 Crohn’s Disease (Regional Enteritis) - Pipeline by Receptos, Inc., H1 2016 113 Crohn’s Disease (Regional Enteritis) - Pipeline by RedHill Biopharma Ltd., H1 2016 114 Crohn’s Disease (Regional Enteritis) - Pipeline by SATT Nord, H1 2016 115 Crohn’s Disease (Regional Enteritis) - Pipeline by Selexys Pharmaceuticals Corporation, H1 2016 116 Crohn’s Disease (Regional Enteritis) - Pipeline by Sigmoid Pharma Limited, H1 2016 117 Crohn’s Disease (Regional Enteritis) - Pipeline by Soligenix, Inc., H1 2016 118 Crohn’s Disease (Regional Enteritis) - Pipeline by Stelic Institute & Co., Inc., H1 2016 119 Crohn’s Disease (Regional Enteritis) - Pipeline by Sylentis S.A.U., H1 2016 120 Crohn’s Disease (Regional Enteritis) - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 121 Crohn’s Disease (Regional Enteritis) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 122 Crohn’s Disease (Regional Enteritis) - Pipeline by Therapeutic Proteins International, LLC, H1 2016 123 Crohn’s Disease (Regional Enteritis) - Pipeline by Tiziana Life Sciences PLC, H1 2016 124 Crohn’s Disease (Regional Enteritis) - Pipeline by Toray Industries, Inc., H1 2016 125 Crohn’s Disease (Regional Enteritis) - Pipeline by Trino Therapeutics Limited, H1 2016 126 Crohn’s Disease (Regional Enteritis) - Pipeline by TxCell SA, H1 2016 127 Crohn’s Disease (Regional Enteritis) - Pipeline by Ventria Bioscience, H1 2016 128 Crohn’s Disease (Regional Enteritis) - Pipeline by Virobay Inc., H1 2016 129 Crohn’s Disease (Regional Enteritis) - Pipeline by Xbrane Biopharma AB, H1 2016 130 Assessment by Monotherapy Products, H1 2016 131 Assessment by Combination Products, H1 2016 132 Number of Products by Stage and Target, H1 2016 134 Number of Products by Stage and Mechanism of Action, H1 2016 140 Number of Products by Stage and Route of Administration, H1 2016 145 Number of Products by Stage and Molecule Type, H1 2016 147 Crohn’s Disease (Regional Enteritis) Therapeutics - Recent Pipeline Updates, H1 2016 342 Crohn’s Disease (Regional Enteritis) - Dormant Projects, H1 2016 451 Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..1), H1 2016 452 Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..2), H1 2016 453 Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..3), H1 2016 454 Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..4), H1 2016 455 Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..5), H1 2016 456 Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..6), H1 2016 457 Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..7), H1 2016 458 Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..8), H1 2016 459 Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..9), H1 2016 460 Crohn’s Disease (Regional Enteritis) - Dormant Projects (Contd..10), H1 2016 461 Crohn’s Disease (Regional Enteritis) - Discontinued Products, H1 2016 462 Crohn’s Disease (Regional Enteritis) - Discontinued Products (Contd..1), H1 2016 463 List of Figures Number of Products under Development for Crohn’s Disease (Regional Enteritis), H1 2016 24 Number of Products under Development for Crohn’s Disease (Regional Enteritis) - Comparative Analysis, H1 2016 25 Number of Products under Development by Companies, H1 2016 26 Number of Products under Investigation by Universities/Institutes, H1 2016 34 Comparative Analysis by Late Stage Development, H1 2016 35 Comparative Analysis by Clinical Stage Development, H1 2016 36 Comparative Analysis by Early Stage Products, H1 2016 37 Assessment by Monotherapy Products, H1 2016 131 Number of Products by Top 10 Targets, H1 2016 133 Number of Products by Stage and Top 10 Targets, H1 2016 133 Number of Products by Top 10 Mechanism of Actions, H1 2016 139 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 139 Number of Products by Top 10 Routes of Administration, H1 2016 144 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 144 Number of Products by Top 10 Molecule Types, H1 2016 146 Number of Products by Stage and Top 10 Molecule Types, H1 2016 146

4D Pharma Plc 4SC AG AB Science SA AbbVie Inc. Alfa Wassermann S.p.A Amgen Inc. Ampio Pharmaceuticals, Inc. Arena Pharmaceuticals, Inc. Avaxia Biologics, Inc. BioAtla, LLC BIOCAD BioLingus AG Bionovis SA BioTherapeutics Inc. Boehringer Ingelheim GmbH Calypso Biotech SA Celgene Corporation Celltrion, Inc. ChemoCentryx, Inc. ChironWells GmbH Chong Kun Dang Pharmaceutical Corp. CLL Pharma Commence Bio, Inc. Daiichi Sankyo Company, Limited DBV Technologies S.A. Effimune SAS Eisai Co., Ltd. Eli Lilly and Company Enterome Bioscience SA Enzo Biochem, Inc. Epirus Biopharmaceuticals, Inc. Ferring International Center S.A. Galapagos NV Genentech, Inc. Genfit SA Genor BioPharma Co., Ltd. Gilead Sciences, Inc. Idera Pharmaceuticals, Inc. Immune Response BioPharma, Inc. Inbiopro Solutions Pvt. Ltd. Innovate Biopharmaceuticals, Inc. Innovent Biologics, Inc. Johnson & Johnson Jyant Technologies, Inc. Kineta, Inc. Kymab Limited Kyorin Pharmaceutical Co., Ltd. Mabion SA MedImmune, LLC Mesoblast Limited Mitsubishi Tanabe Pharma Corporation Momenta Pharmaceuticals, Inc. Mycenax Biotech Inc. Neovacs SA Ocata Therapeutics, Inc. Oncobiologics, Inc. Oncodesign SA Pfenex Inc. Pfizer Inc. Pluristem Therapeutics Inc. Protagonist Therapeutics Inc. Protalix BioTherapeutics, Inc. Qu Biologics Inc. Re-Pharm Limited Receptos, Inc. RedHill Biopharma Ltd. SATT Nord Selexys Pharmaceuticals Corporation Sigmoid Pharma Limited Soligenix, Inc. Stelic Institute & Co., Inc. Sylentis S.A.U. TaiwanJ Pharmaceuticals Co., Ltd. Takeda Pharmaceutical Company Limited Therapeutic Proteins International, LLC Tiziana Life Sciences PLC Toray Industries, Inc. Trino Therapeutics Limited TxCell SA Ventria Bioscience Virobay Inc. Xbrane Biopharma AB